SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors.
Lu H, Liu C, Velazquez R, Wang H, Dunkl LM, Kazic-Legueux M, Haberkorn A, Billy E, Manchado E, Brachmann SM, Moody SE, Engelman JA, Hammerman PS, Caponigro G, Mohseni M, Hao HX.
Lu H, et al. Among authors: brachmann sm.
Mol Cancer Ther. 2019 Jul;18(7):1323-1334. doi: 10.1158/1535-7163.MCT-18-0852. Epub 2019 May 8.
Mol Cancer Ther. 2019.
PMID: 31068384